Novartis lung cancer drug gets key FDA designation

Cancer specialists expect the lung cancer death rate will continue its upward trend for the next few years.

Novartis lung cancer drug gets key FDA designation

Published: 03:06:01 PM, Fri 15 March 2013 UTC

NEW YORK (AP) — Novartis AG said Friday that its experimental cancer drug LDK378 was designated as a breakthrough therapy by the Food and Drug Administration.

The Swiss drugmaker is studying LDK378 as a treatment for a rare type of metastatic non-small cell lung cancer. It is intended for patients whose cancer progressed during treatment with Pfizer Inc.'s drug Xalkori, or who could not tolerate treatment with Xalkori.

The FDA created the breakthrough therapy program in 2012 as a way to speed up the approval process for drugs that could be significant improvements in the treatment of serious or life-threatening diseases from what's currently on the market.

Novartis is running two mid-stage clinical trials of LDK378. It plans to start late-stage testing later in 2013 and to file for marketing approval in early 2014.

Shares of Novartis rose 96 cents to $69.91 in late morning trading. The stock has changed hands between $51.20 and $70.24 in the past 52 weeks.

Tags: pfizer inc., food and drug administration, novartis ag, novartis, patients, cents, health, breast cancer, metastasis, drug administration, drugs, friday, epidemiology, pharmaceutical industry, hands, treatment, cancer, food, new york, breakthrough therapy, breakthrough therapy program, marketing approval, approval process, life-threatening diseases, significant improvements, late morning trading, cancer drug, experimental cancer drug, lung cancer, late-stage testing, rare type, swiss drugmaker, non-small cell lung carcinoma, mid-stage clinical trials, novartis lung cancer, key fda designation, metastatic non-small cell, ldk378, drug xalkori